Advertisement
Advertisement

ATRC

ATRC logo

AtriCure, Inc.

37.13
USD
Sponsored
+0.93
+2.57%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

37.11

-0.02
-0.05%

ATRC Earnings Reports

Positive Surprise Ratio

ATRC beat 30 of 40 last estimates.

75%

Next Report

Date of Next Report
Feb 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
$142.24M
/
-$0.09
Implied change from Q3 25 (Revenue/ EPS)
+5.94%
/
+800.00%
Implied change from Q4 24 (Revenue/ EPS)
+14.46%
/
+12.50%

AtriCure, Inc. earnings per share and revenue

On Oct 29, 2025, ATRC reported earnings of -0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.11 USD, resulting in a 91.46% surprise. Revenue reached 134.27 million, compared to an expected 133.88 million, with a 0.29% difference. The market reacted with a -3.81% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 142.24 million USD, implying an increase of 800.00% EPS, and increase of 5.94% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
logo
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
logo
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.56
Surprise
0.00%
logo
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
logo
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
logo
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
logo
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
logo
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
logo
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
logo
Haemonetics Corporation
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.26
Actual
$1.31
Surprise
+3.75%
FAQ
For Q3 2025, AtriCure, Inc. reported EPS of -$0.01, beating estimates by 91.46%, and revenue of $134.27M, 0.29% above expectations.
The stock price moved down -3.81%, changed from $35.44 before the earnings release to $34.09 the day after.
The next earning report is scheduled for Feb 17, 2026.
Based on 11 analysts, AtriCure, Inc. is expected to report EPS of -$0.09 and revenue of $142.24M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement